Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdy080
复制
发表时间：
2018-10-01
影响因子：
50.5
通讯作者：
Ladetto, M.
中科院分区：
文献类型：
--
作者：
Eichenauer, D. A.;Aleman, B. M. P.;Ladetto, M.
欧盟霍奇金淋巴瘤（HL）的粗发病率为2.3，死亡率为0.4例/10万人/年。 20-40 岁的年轻人最常受到影响。被诊断患有 HL 的男性略多于女性。在组织学上，占所有 HL 病例约 95% 的经典 HL (cHL) 与占所有 HL 病例约 5% 的结节性淋巴细胞为主型 HL (NLPHL) 不同。
The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.3, the mortality 0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected. Slightly more men than women are diagnosed with HL. Histologically, classical HL (cHL) accounting for∼ 95% of all HL cases is distinguished from nodular lymphocyte-predominant HL (NLPHL) representing∼ 5% of all HL cases.